AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, showed disease-free survival ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...